AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (40/320 mg, DP, group A)
Number of subjects: 106
Study 18637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (20/120 mg tablets, AL, group B)
Number of subjects: 106
Study 18637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 106
Study 18637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 106
Study 18637586 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AL and DP
Number of subjects: 106
Study 15930065 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive therapy (N=15)
Number of subjects: 45
Study 15930065 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cognitive therapy (N=15)
Number of subjects: 45
Study 15930065 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (N=15)
Number of subjects: 45
Study 12912780 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling aimed at decreasing intake of saturated fat and cholesterol, provided since the children were 8 months old.
Number of subjects: 435
Study 12912780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling).
Number of subjects: 435
Study 10513802 — intervention group
Group type: EXPERIMENTAL
Intervention: Global statistical tests (GSTs)
Number of subjects: 3
Study 10513802 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate
Number of subjects: 3
Study 10513802 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint swelling and joint tenderness
Number of subjects: 3
Study 10513802 — intervention group
Group type: COMPARATOR
Intervention: ACR criteria
Number of subjects: 3
Study 8562399 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive ELISA assay for platelet HPA1a typing
Number of subjects: 475
Study 8562399 — intervention group
Group type: COMPARATOR
Intervention: Control samples stored as whole blood
Number of subjects: 475
Study 1881502 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent cimetidine 800 mg
Number of subjects: 10
Study 1881502 — intervention group
Group type: COMPARATOR
Intervention: Maalox (liquid aluminium/magnesium hydroxide antacid)
Number of subjects: 10
Study 754193 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to artificial electromagnetic (ac) fields
Number of subjects: 14
Study 754193 — intervention group
Group type: COMPARATOR
Intervention: Shielding of the kidney area
Number of subjects: 14
Study 754193 — intervention group
Group type: COMPARATOR
Intervention: Shielding of the head
Number of subjects: 14
Study 31932171 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 1400
Study 31932171 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical assessment as directed by NICE CG95 guideline
Number of subjects: 1400
Study 30862658 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 24 weeks
Number of subjects: 49
Study 30862658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28098097 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa oil (2.5 mL, once daily, per orally) along with conservative management for 12 weeks
Number of subjects: 0
Study 28098097 — intervention group
Group type: COMPARATOR
Intervention: Conservative management of diabetic nephropathy
Number of subjects: 0
Study 26148204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir arm (TDF/emtricitabine)
Number of subjects: 1096
Study 26148204 — intervention group
Group type: COMPARATOR
Intervention: Abacavir arm
Number of subjects: 1096
Study 23874469 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating music
Number of subjects: 0
Study 23874469 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 0
Study 23874469 — intervention group
Group type: COMPARATOR
Intervention: Metronome stimuli
Number of subjects: 0
Study 21797111 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg orally daily for six months plus carboplatin (AUC 7) intravenously every four weeks for up to six doses
Number of subjects: 40
Study 21797111 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 7) intravenously every four weeks for up to six doses
Number of subjects: 40
Study 19254585 — intervention group
Group type: COMPARATOR
Intervention: fFN 0 ng/mL
Number of subjects: 563
Study 19254585 — intervention group
Group type: EXPERIMENTAL
Intervention: fFN 1-49 ng/mL
Number of subjects: 563
Study 19254585 — intervention group
Group type: EXPERIMENTAL
Intervention: fFN 50-199 ng/mL
Number of subjects: 563
Study 19254585 — intervention group
Group type: EXPERIMENTAL
Intervention: fFN > 200 ng/mL
Number of subjects: 563
Study 17532241 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching regimens (decreased prescribed hours)
Number of subjects: 560
Study 17532241 — intervention group
Group type: COMPARATOR
Intervention: Patching for only 2 hours
Number of subjects: 560
Study 16179209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical imaging protocol using MR acquisition and analysis methods
Number of subjects: 10
Study 12843168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion
Number of subjects: 58
Study 12843168 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone administration
Number of subjects: 58
Study 10073739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine hydrochloride
Number of subjects: 18
Study 10073739 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocysteamine
Number of subjects: 18
Study 10073739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine bitartrate
Number of subjects: 18
Study 10073739 — intervention group
Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 18
Study 10073739 — intervention group
Group type: COMPARATOR
Intervention: Cysteamine hydrochloride vs Phosphocysteamine
Number of subjects: 18
Study 10073739 — intervention group
Group type: COMPARATOR
Intervention: Cysteamine hydrochloride vs Cysteamine bitartrate
Number of subjects: 18
Study 8849352 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (5mg MTX/week plus 50 mg AZA/day to 7.5 mg MTX/week plus 100 mg AZA/day)
Number of subjects: 209
Study 8849352 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 50-150 mg/day
Number of subjects: 209
Study 8849352 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 5-15 mg/week
Number of subjects: 209
Study 8849352 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 209
Study 8849352 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment and Azathioprine (AZA)
Number of subjects: 209
Study 2309991 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) with propofol and alfentanil infusion
Number of subjects: 40
Study 2309991 — intervention group
Group type: COMPARATOR
Intervention: Balanced Anaesthesia (BA) with thiopental and fentanyl
Number of subjects: 40
Study 345678 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Feedback (RFB)
Number of subjects: 24
Study 345678 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 31910030 — intervention group
Group type: COMPARATOR
Intervention: Glucose minimal model (MM)
Number of subjects: 66
Study 31910030 — intervention group
Group type: COMPARATOR
Intervention: NEFA minimal model (MM)
Number of subjects: 66
Study 31910030 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fatty acids
Number of subjects: 66
Study 29707579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 91
Study 29707579 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 91
Study 26821247 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and yoga intervention
Number of subjects: 0
Study 26821247 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 24473367 — intervention group
Group type: COMPARATOR
Intervention: Normal-dose CTPA (100-kVp tube energy and 100-mL CM)
Number of subjects: 501
Study 24473367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CTPA (80-kVp tube energy and 75-mL CM)
Number of subjects: 501
Study 22104075 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal guidewire-assisted NGT insertion with manual forward laryngeal displacement (group 1)
Number of subjects: 480
Study 22104075 — intervention group
Group type: COMPARATOR
Intervention: Head flexion and lateral neck pressure (group 2)
Number of subjects: 480
Study 19946699 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 26 Hz for five 1-min bouts
Number of subjects: 12
Study 19946699 — intervention group
Group type: COMPARATOR
Intervention: Non-WBV treatment (stretching of the plantar flexors at end range of dorsiflexion for five 1-min bouts)
Number of subjects: 12
Study 19946699 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 12
Study 18721711 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 0.4%
Number of subjects: 56
Study 18721711 — intervention group
Group type: COMPARATOR
Intervention: bromfenac 0.09%
Number of subjects: 56
Study 15649853 — intervention group
Group type: COMPARATOR
Intervention: Rac‐formoterol 36 microg
Number of subjects: 46
Study 15649853 — intervention group
Group type: COMPARATOR
Intervention: (R;R)‐formoterol 18 microg
Number of subjects: 46
Study 15649853 — intervention group
Group type: COMPARATOR
Intervention: (S;S)‐formoterol 18 microg
Number of subjects: 46
Study 15649853 — intervention group
Group type: EXPERIMENTAL
Intervention: Rac‐formoterol and (R;R)‐formoterol
Number of subjects: 46
Study 15649853 — intervention group
Group type: EXPERIMENTAL
Intervention: (R;R)‐formoterol
Number of subjects: 46
Study 12236642 — intervention group
Group type: EXPERIMENTAL
Intervention: SyntacSprint (SS) and Tetric Ceram (TC) without base material
Number of subjects: 48
Study 12236642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract as base material with Tetric Ceram (TC)
Number of subjects: 48
Study 12236642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer as base material with Tetric Ceram (TC)
Number of subjects: 48
Study 12236642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelon-fil as base material with Tetric Ceram (TC)
Number of subjects: 48
Study 12669742 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 60 mg/day
Number of subjects: 68
Study 12669742 — intervention group
Group type: COMPARATOR
Intervention: Etidronate 400 mg/day
Number of subjects: 68
Study 12669742 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 68
Study 12669742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8697058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 5 mg/day
Number of subjects: 0
Study 8697058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg/day
Number of subjects: 0
Study 8697058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine doses varying from 1 to 30 mg
Number of subjects: 0
Study 8697058 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine (various doses)
Number of subjects: 0
Study 2132640 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine 25 mg
Number of subjects: 8
Study 2132640 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine 50 mg
Number of subjects: 8
Study 2132640 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine 75 mg
Number of subjects: 8
Study 2132640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 443256 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day of prednisolone
Number of subjects: 24
Study 443256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31361535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2)
Number of subjects: 1516
Study 31361535 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (15 mg/kg)
Number of subjects: 1516
Study 31361535 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pemetrexed and bevacizumab
Number of subjects: 1516
Study 27260003 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 12
Study 27260003 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-IPC
Number of subjects: 12
Study 27260003 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 12
Study 27260003 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC and 24-IPC
Number of subjects: 12
Study 25729933 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20
Study 25729933 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (moderate enteral nutritional support)
Number of subjects: 20
Study 23940710 — intervention group
Group type: EXPERIMENTAL
Intervention: High proanthocyanidin intake (highest tertile)
Number of subjects: 948
Study 21873661 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated POAG patients attending follow-up study (n = 47)
Number of subjects: 66
Study 21873661 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak IOP
Number of subjects: 66
Study 21873661 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour IOP
Number of subjects: 66
Study 21873661 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP fluctuation
Number of subjects: 66
Study 21873661 — intervention group
Group type: COMPARATOR
Intervention: Comparison of glaucomatous eye vs. nonglaucomatous eye
Number of subjects: 66
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 0.1 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 0.5 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 1.5 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 2 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 1 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 2 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 3 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 1 mg/kg followed by infusion of 4 mg/kg
Number of subjects: 60
Study 19808128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16700280 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 16700280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 60
Study 16700280 — intervention group
Group type: COMPARATOR
Intervention: Sodium Chloride (Placebo)
Number of subjects: 60
Study 12911451 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (n = 36)
Number of subjects: 74
Study 12911451 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy (n = 38)
Number of subjects: 74
Study 11093025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment for 10 seconds (0.069 ml of ozone)
Number of subjects: 40
Study 11093025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment for 20 seconds (0.138 ml of ozone)
Number of subjects: 40
Study 11093025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment for 10 seconds on S. mutans
Number of subjects: 40
Study 11093025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment for 10 seconds on S. sobrinus
Number of subjects: 40
Study 9194719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 400 mg 5 times a day for 3 weeks
Number of subjects: 287
Study 9194719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 1493321 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of posterior mitral leaflet (PML) during mitral prosthesis implantation (MPI)
Number of subjects: 95
Study 1493321 — intervention group
Group type: COMPARATOR
Intervention: Mitral prosthesis implantation (MPI) without preservation of PML
Number of subjects: 95
Study 3923081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding during radiation therapy
Number of subjects: 26
Study 31566666 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS)
Number of subjects: 354
Study 31566666 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 354
Study 29848044 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops linking young women with existing government structural support programmes
Number of subjects: 3516
Study 29848044 — intervention group
Group type: COMPARATOR
Intervention: Excluding Ipelegeng (a part-time minimum wage rotating employment scheme)
Number of subjects: 3516
Study 29848044 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of all programmes
Number of subjects: 3516
Study 25355728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg
Number of subjects: 185
Study 25355728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg
Number of subjects: 185
Study 25355728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 25355728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (both doses)
Number of subjects: 185
Study 25227656 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 79
Study 22004690 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 71
Study 22004690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 20196635 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare-up group
Number of subjects: 221
Study 20196635 — intervention group
Group type: COMPARATOR
Intervention: Antagonist group
Number of subjects: 221
Study 18586174 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 126
Study 18586174 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 126
Study 18586174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 15937757 — intervention group
Group type: EXPERIMENTAL
Intervention: PAmAb (0.3, 1.0, and 3.0 mg/kg intramuscular; 1.0, 3.0, 10, 20, and 40 mg/kg intravenous)
Number of subjects: 105
Study 15937757 — intervention group
Group type: EXPERIMENTAL
Intervention: PAmAb (intramuscular and intravenous)
Number of subjects: 105
Study 15937757 — intervention group
Group type: EXPERIMENTAL
Intervention: PAmAb (biological activity)
Number of subjects: 105
Study 15937757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 105
Study 12209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus bolus 5-fluorouracil (5-FU)
Number of subjects: 0
Study 12209671 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0
Study 10970079 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 60
Study 10970079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 60
Study 8641910 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony stimulating factor (G-CSF) at a dose of 300 micrograms subcutaneously, administered on Friday, Saturday, and Sunday during the radiotherapy period.
Number of subjects: 15
Study 8641910 — intervention group
Group type: COMPARATOR
Intervention: Large-field radiotherapy without G-CSF (Control group).
Number of subjects: 15
Study 1503284 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone 9 mg.kg‐1.h‐1 for one hour (group M)
Number of subjects: 14
Study 1503284 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 9 mg.kg‐1.h‐1 with fentanyl 7 micrograms.kg‐1.h‐1 for one hour (group MF)
Number of subjects: 14
Study 6742535 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg X kg‐1)
Number of subjects: 10
Study 6742535 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.02 mg X kg‐1)
Number of subjects: 10
Study 31034304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (75 min/week)
Number of subjects: 18
Study 31034304 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic training (MICT) (150 min/week)
Number of subjects: 18
Study 28698692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3
Study 28698692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and Dexmedetomidine
Number of subjects: 3
Study 28698692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 3
Study 28698692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-Dexmedetomidine
Number of subjects: 3
Study 25327485 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 150 mg/day
Number of subjects: 95
Study 25327485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acarbose)
Number of subjects: 95
Study 24502072 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 100 micrograms
Number of subjects: 60
Study 24502072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21986123 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist laparotomy pads (PAD group)
Number of subjects: 51
Study 21986123 — intervention group
Group type: COMPARATOR
Intervention: Deep pericardial traction sutures (DPS group)
Number of subjects: 51
Study 18372134 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 444
Study 17072954 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose syrup + levodopa for 3 days (Group 1)
Number of subjects: 139
Study 17072954 — intervention group
Group type: COMPARATOR
Intervention: Placebo for levodopa + 10% sucrose syrup for 3 days (Group 2)
Number of subjects: 139
Study 17072954 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose syrup + levodopa for 7 days (Group 3)
Number of subjects: 139